Cognition Therapeutics Secures Key Patent for Lead Drug Zervimesine, Extending Protection Through 2045
CGTX has more than doubled off its 52-week low of $0.25.
Summary
Cognition Therapeutics announced a Notice of Allowance for a new composition of matter patent covering a polymorphic crystalline form of its lead drug candidate, zervimesine (CT1812). This patent extends protection through 2045, with a potential extension to 2050, and covers a more stable formulation of the drug. This follows recent positive news regarding zervimesine, including successful FDA meetings in May and its formal advancement into a registrational program for Dementia with Lewy Bodies (DLB). Extending patent protection for a lead candidate by many years significantly enhances its long-term commercial value and de-risks its future revenue stream as it progresses into late-stage clinical development.
At the time of this announcement, CGTX was trading at $1.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $108.3M. The 52-week trading range was $0.25 to $3.83. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.